Home > Oncology > Bayer’s Nubeqa drug significantly prolongs survival in prostate cancer trial

Bayer’s Nubeqa drug significantly prolongs survival in prostate cancer trial


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The New England Journal of Medicine
Reuters - 17/02/2022 - Bayer said a therapy mix including its Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, underpinning prospects for the drug to become a major sales driver. Nubeqa, when combined with standard therapy, reduced the risk of dying during the trial period by 32.5% in a comparison to standard therapy alone, the German company said in a statement on Thursday, citing trial results. Nubeqa, also known as darolutamide and jointly developed with Finnish drugmaker Orion, is already approved in non-metastatic prostate cancer that cannot be treated with standard hormone therapy, and the new results point to a larger market opportunity if regulators clear the wider use. Bayer, which is paying billions to settle U.S. claims its Roundup weedkiller caused cancer, needs to strengthen its drug development pipeline as its two pharmaceutical best-sellers, stroke prevention pill Xar...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on